China Appetite For HPV Vaccine Delivers Surprise For Merck
When Merck realized that demand in China is so large for its HPV vaccine Gardasil, the US company wanted to understand more about the market, but a coordinated pre-launch awareness campaign appears to have helped.
You may also be interested in...
The decision to expand the HPV vaccination program in England to boys comes as Merck & Co sees "an unprecedented increase in global demand" for Gardasil.
Following a priority review, Shingrix may become the next hit vaccine in China as millions seek preventative care, but GSK is being cautious over supply plans.
Products old, new and reimbursed were the driving force for foreign drug firms including AstraZeneca, Merck and Pfizer and Sanofi to smash growth in China in the first quarter.